Akoya BioSciences shares are trading higher after the company announced that the company's PhenoCycler Fusion and PhenoImager HT spatial proteomics platforms will be used to analyze tissue samples as part of the MANIFEST program.
Portfolio Pulse from Benzinga Newsdesk
Akoya BioSciences shares rose following the announcement that its PhenoCycler Fusion and PhenoImager HT platforms will be utilized in the MANIFEST program for tissue sample analysis.
October 07, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akoya BioSciences' stock is trading higher due to the announcement that its spatial proteomics platforms will be used in the MANIFEST program, indicating increased demand and validation for its technology.
The use of Akoya's platforms in the MANIFEST program suggests increased demand and validation for its technology, likely boosting investor confidence and driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100